Experimental drug iptacopan aids man with lupus-associated aHUS
After standard therapies failed, a 59-year-old man with lupus-related atypical hemolytic uremic syndrome (aHUS) improved when doctors gave him the oral medication iptacopan alongside one cycle of immunosuppressant rituximab, according to a case report from Italy. Iptacopan, marketed as Fabhalta, is an oral therapy approved for other diseases driven…